{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:05:15Z","timestamp":1762430715698,"version":"3.33.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T00:00:00Z","timestamp":1363910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation. Because of the high mortality rate associated with active tuberculosis infections in transplant recipients, guidelines from the American Thoracic Society recommend treatment for latent tuberculosis in this population. However, the choice of treatments is often difficult because liver transplant recipients may be more sensitive to isoniazid hepatotoxicity, and rifampin has significant drug interactions with the calcineurin inhibitors used for immunosuppression. Two prior case reports described success with the use of rifabutin, a rifampin alternative, as part of a multidrug treatment regimen for active tuberculosis in posttransplant patients; however, there is no prior literature describing any experience with rifabutin for the treatment of latent tuberculosis in the posttransplant setting. We present a summary of tacrolimus drug levels and corresponding dose requirements for a single posttransplant patient during the administration of 3 different latent tuberculosis drug regimens: rifampin alone, rifampin plus ketoconazole, and rifabutin. In this patient's case, rifabutin allowed the maintenance of adequate tacrolimus levels, although an approximate 2.5-fold increase in the dose was required. Rifampin alone was associated with inadequate immunosuppressant levels, and rifampin plus ketoconazole was associated with a problematically prolonged QT interval and concerns about inadequate tuberculosis treatment. <jats:italic toggle=\"yes\">Liver Transpl 19:457\u2013461, 2013<\/jats:italic>. \u00a9 2013 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.23622","type":"journal-article","created":{"date-parts":[[2013,3,23]],"date-time":"2013-03-23T09:13:22Z","timestamp":1364030002000},"page":"457-461","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation"],"prefix":"10.1097","volume":"19","author":[{"given":"Matthew D.","family":"Hickey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter V.","family":"Chin-Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20250124","doi-asserted-by":"crossref","first-page":"306314","DOI":"10.1002\/lt.22203","article-title":"Detection and management of latent tuberculosis in liver transplant patients.","volume":"17","author":"Jafri","year":"2011","journal-title":"Liver Transpl"},{"key":"R2-17-20250124","doi-asserted-by":"crossref","first-page":"12661277","DOI":"10.1086\/514993","article-title":"Mycobacterium tuberculosis infection in solidorgan transplant recipients: impact and implications for management.","volume":"27","author":"Singh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R3-17-20250124","doi-asserted-by":"crossref","first-page":"774777","DOI":"10.1097\/INF.0b013e3182564ec7","article-title":"Tuberculosis in pediatric solid organ and hematopoietic stem cell transplant recipients.","volume":"31","author":"Vecino","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R4-17-20250124","doi-asserted-by":"crossref","first-page":"894906","DOI":"10.1002\/lt.21709","article-title":"Tuberculosis in liver transplant recipients: a systematic review and metaanalysis of individual patient data.","volume":"15","author":"Holty","year":"2009","journal-title":"Liver Transpl"},{"key":"R5-17-20250124","doi-asserted-by":"crossref","first-page":"613618","DOI":"10.1097\/MOT.0b013e3283324dfc","article-title":"Mycobacterium tuberculosis infection in transplant recipients: early diagnosis and treatment of resistant tuberculosis.","volume":"14","author":"Holty","year":"2009","journal-title":"Curr Opin Organ Transpl"},{"key":"R6-17-20250124","first-page":"16501653","article-title":"Recommendations for use of an isoniazidrifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R7-17-20250124","doi-asserted-by":"crossref","first-page":"12761284","DOI":"10.1086\/597590","article-title":"Tuberculosis in solidorgan transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.","volume":"48","author":"Aguado","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R9-17-20250124","first-page":"151","article-title":"American Thoracic Society.","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"R11-17-20250124","doi-asserted-by":"crossref","first-page":"11361146","DOI":"10.1002\/lt.22125","article-title":"Acute liver failure due to antitubercular therapy: strategy for antitubercular treatment before and after liver transplantation.","volume":"16","author":"Ichai","year":"2010","journal-title":"Liver Transpl"},{"key":"R12-17-20250124","doi-asserted-by":"crossref","first-page":"695704","DOI":"10.1097\/TP.0b013e3181ecea8d","article-title":"Tuberculosis in renal transplant recipients: the evidence for prophylaxis.","volume":"90","author":"Currie","year":"2010","journal-title":"Transplantation"},{"key":"R13-17-20250124","doi-asserted-by":"crossref","first-page":"634637","DOI":"10.1093\/ndt\/gfp489","article-title":"Use of isoniazid chemoprophylaxis in renal transplant recipients.","volume":"25","author":"Naqvi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R14-17-20250124","doi-asserted-by":"crossref","first-page":"99108","DOI":"10.1111\/j.1399-3062.2005.00103.x","article-title":"Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy.","volume":"7","author":"Vikrant","year":"2005","journal-title":"Transpl Infect Dis"},{"key":"R15-17-20250124","doi-asserted-by":"crossref","first-page":"229234","DOI":"10.1111\/j.1399-0012.2006.00630.x","article-title":"Liver transplantation without isoniazid prophylaxis for recipients with a history of tuberculosis.","volume":"21","author":"Nagai","year":"2007","journal-title":"Clin Transplant"},{"key":"R16-17-20250124","doi-asserted-by":"crossref","first-page":"15571562","DOI":"10.1097\/01.tp.0000266578.45634.4f","article-title":"Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.","volume":"83","author":"Jahng","year":"2007","journal-title":"Transplantation"},{"key":"R17-17-20250124","doi-asserted-by":"crossref","first-page":"892895","DOI":"10.1097\/00007890-200209270-00029","article-title":"Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis.","volume":"74","author":"Singh","year":"2002","journal-title":"Transplantation"},{"key":"R18-17-20250124","doi-asserted-by":"crossref","first-page":"689697","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"R20-17-20250124","doi-asserted-by":"crossref","first-page":"985992","DOI":"10.1001\/archinte.162.9.985","article-title":"Rifampin and rifabutin drug interactions: an update.","volume":"162","author":"Finch","year":"2002","journal-title":"Arch Int Med"},{"key":"R21-17-20250124","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1208\/aapsj060428","article-title":"Exposureresponse relationships and drug interactions of sirolimus.","volume":"6","author":"Zimmerman","year":"2004","journal-title":"AAPS J"},{"key":"R22-17-20250124","first-page":"144146","article-title":"Combined use of astemizole and ketoconazole resulting in torsade de pointes.","volume":"96","author":"Tsai","year":"1997","journal-title":"J Formos Med Assoc"},{"key":"R23-17-20250124","first-page":"10021003","article-title":"Torsades de pointes after treatment with terfenadine and ketoconazole.","volume":"13","author":"Zimmermann","year":"1992","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"R24-17-20250124","first-page":"S15S21","article-title":"The clinical pharmacokinetics of rifabutin.","volume":"22","author":"Blaschke","year":"1996","journal-title":"Clin Infect Dis"},{"key":"R26-17-20250124","first-page":"341347","article-title":"Rifabutin for the treatment of newlydiagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Rifabutin Study Group.","volume":"75","author":"GonzalezMontaner","year":"1994","journal-title":"Tuber Lung Dis"},{"key":"R27-17-20250124","doi-asserted-by":"crossref","first-page":"14621467","DOI":"10.1164\/ajrccm.154.5.8912765","article-title":"Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis.","volume":"154","author":"McGregor","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"R28-17-20250124","doi-asserted-by":"crossref","first-page":"210218","DOI":"10.1016\/S0962-8479(05)80007-3","article-title":"A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV1 associated tuberculosis. A singleblind randomized evaluation in Ugandan patients with HIV1 infection and pulmonary tuberculosis.","volume":"76","author":"Schwander","year":"1995","journal-title":"Tuber Lung Dis"},{"key":"R29-17-20250124","first-page":"e59e63","article-title":"Treatment of tuberculosis with rifabutin in a renal transplant recipient.","volume":"44","author":"LopezMontes","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R30-17-20250124","doi-asserted-by":"crossref","first-page":"11681173","DOI":"10.1016\/S1053-2498(02)01189-0","article-title":"Multidrugresistant tuberculosis in a lung transplant recipient.","volume":"22","author":"Lee","year":"2003","journal-title":"J Heart Lung Transplant"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23622","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201304000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:26:16Z","timestamp":1737739576000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201304000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.23622","relation":{},"ISSN":["1527-6465"],"issn-type":[{"type":"print","value":"1527-6465"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}